Adding Beigene‘s experimental therapy tislelizumab to standard first-line chemotherapy significantly delays disease progression or death in patients with advanced squamous non-small cell lung cancer (NSCLC), data from a Phase 3 clinical trial shows. The combination also increased the proportion of patients responding to treatment and the duration of such responses, compared to chemotherapy only. The findings were presented at the 2020 American Society of Clinical Oncology (ASCO) annual meeting — held virtually due to the COVID-19 pandemic —…
You must be logged in to read/download the full post.
The post Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trial appeared first on BioNewsFeeds.